Instil Bio

Instil Bio Payables Turnover

The Payables Turnover Ratio of Instil Bio (TIL) as of Nov 21, 2026 is 0.69. In the previous year, Payables Turnover Ratio was 5.48 — a change of -87.49% (lower).

Payables Turnover

0.69

YoY

-87.49%

Last updated:

Payables Turnover Ratio of Instil Bio is 2025 0.69 . Payables Turnover Ratio of Instil Bio was 2024 5.48 . It decreases by -87.49% lower compared to the previous year.

The Instil Bio Payables Turnover history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Payables Turnover
Date
Payables Turnover
Jan 1, 2019
0.02 USD
Jan 1, 2021
0.49 USD
Jan 1, 2022
2.54 USD
Jan 1, 2023
3.92 USD
Jan 1, 2024
5.48 USD
Jan 1, 2025
0.69 USD
The Instil Bio Payables Turnover history
YEARPayables TurnoverYoY
0.69-87.49%
5.48+39.60%
3.92+54.62%
2.54+413.49%
0.49+2,319.37%
0.02—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Instil Bio Stock analysis

What does Instil Bio do? Instil Bio Inc develops autologous tumor infiltrating lymphocyte (TIL) therapies for cancer treatment, focusing on advanced melanoma and solid tumors. The company's lead product ITIL-168 targets PD-1-inhibitor relapsed or refractory advanced melanoma, while ITIL-306 uses its Co-Stimulatory Antigen Receptor (CoStAR) platform to recognize folate receptor alpha (FOLR1) on tumors like ovarian, uterine, NSCLC, and renal cancer. The company advances these therapies through clinical development as a clinical-stage biopharmaceutical firm. Its pipeline includes autologous TIL therapies and genetically engineered CoStAR-TIL therapies for multiple cancer types. Instil Bio Inc generates revenue through the development and potential future commercialization of its TIL therapy pipeline. The company's primary focus is on advancing ITIL-168 for advanced melanoma and ITIL-306 for FOLR1-expressing tumors, targeting patients with relapsed or refractory cancers. The firm's clinical-stage status indicates it is currently in development phase without commercial products, so revenue likely comes from partnerships, grants, or future product sales once approved. The company's key segments are cancer patients requiring novel cell therapies, particularly those with melanoma and FOLR1-positive solid tumors. Instil Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Instil Bio stock

Payables Turnover Ratio of Instil Bio is 0.69 in 2025.

Payables Turnover Ratio of Instil Bio changed from 5.48 to 0.69, representing a -87.49% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Payables Turnover Ratio Instil Bio since 2006 – with annual values, charts, and detailed analysis.

Payables turnover measures how quickly a company pays its suppliers. Lower turnover may indicate better payment terms or cash flow management.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Payables Turnover Ratio's Instil Bio with sector peers and the industry average to assess whether it is attractive.

To evaluate Payables Turnover Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Payables Turnover Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Instil Bio

All Key Metrics — Instil Bio